Here, drug accumulation within breast cancer cells was significantly improved because of the endocytosis of an anti-CD276 antibody (CD276Ab) by tumor cells, followed by its subcellular localization in both early endosomes and lysosomes [15], thereby demonstrating the effectivity of utilizing antibodies to drive the drugs to the tumor. Here, CD276 is linked to neoplasm.